Product Information
DEXLANSOPRAZOLE DR 30 MG CAP is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $3.7727 per EA under NDC 00378208593. Its NADAC has been published 134 times since Mar 13, 2024.
FDA first approved this application on Jan 19, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378208593
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE PELLETS
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DEXLANSOPRAZOLE SESQUIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA205205FDA Approved
1/19/2024
TE Code
AB
On Market Since
1/22/2024
Pharmacological Classes
Price Statistics
The NADAC for DEXLANSOPRAZOLE DR 30 MG CAP has been published 134 times since Mar 13, 2024, and over the history we have for it it has declined 45.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.7727 per EA |
|---|---|
| All-time high | $7.0465 (Apr 10, 2024) |
| All-time low | $3.7727 (Sep 23, 2026) |
| 52-week high | $4.8639 |
| 52-week low | $3.7727 |
| Median price | $4.5840 |
| Average price | $4.7368 |
| Largest weekly change | +32.8% (Aug 21, 2024) |
| Weeks tracked | 134 |
| Tracking since | Mar 13, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dexlansoprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXLANSOPRAZOLE DR 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DEXLANSOPRAZOLE DR 30 MG CAP, manufactured by Mylan Pharmaceuticals Inc., is $3.7727 per EA (NDC 00378208593), effective Sep 30, 2026.
How has the price of DEXLANSOPRAZOLE DR 30 MG CAP changed over time?
Over the history we have for it, the NADAC for DEXLANSOPRAZOLE DR 30 MG CAP has declined 45.3%. It has been tracked across 134 weekly CMS publications since Mar 13, 2024.
What are the highest and lowest recorded NADAC prices for DEXLANSOPRAZOLE DR 30 MG CAP?
Since Mar 13, 2024, the NADAC for DEXLANSOPRAZOLE DR 30 MG CAP has ranged from a low of $3.7727 (Sep 23, 2026) to a high of $7.0465 (Apr 10, 2024), with a median of $4.5840 per EA.
Are there cheaper alternatives to DEXLANSOPRAZOLE DR 30 MG CAP?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DEXLANSOPRAZOLE DR 30 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures DEXLANSOPRAZOLE DR 30 MG CAP?
DEXLANSOPRAZOLE DR 30 MG CAP (NDC 00378208593) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.